Physician profile
Peter Aziz
NPI 1649629015
$10,455.13
in general payments reported to CMS, 2019-2025
11 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $19.38 · 2021: $19.00 · 2022: $217 · 2023: $4,565 · 2024: $4,060 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,555 · Travel and Lodging: $4,076 · Education: $1,000 · Gift: $54.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,554.94 |
| Travel and Lodging | $4,075.72 |
| Education | $1,000.00 |
| Gift | $54.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caldera Medical, INC | $2,646.29 | 2023-2025 | Desara |
| Axonics, INC. | $1,981.44 | 2022-2024 | Axonics, Bulkamid |
| Medtronic, INC. | $1,903.22 | 2021-2024 | Interstim |
| Coloplast Corp | $1,468.89 | 2023 | Altis |
| Intuitive Surgical, INC. | $1,028.98 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Boston Scientific Corporation | $842.47 | 2025 | Axonics |
| Novartis Pharmaceuticals Corporation | $350.16 | 2019 | |
| Medtronic USA, INC. | $151.11 | 2019-2020 | |
| Applied Medical Resources Corporation | $50.27 | 2023 | |
| Merck Sharp & Dohme LLC | $18.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.